The company reportedly paid falsified consulting fees to encourage docs to use their devices.

Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.